MgShell, a medtech company specialising in the development of innovative technologies for the treatment of eye diseases, announces the closing of a EUR 1,140,000 investment round. The transaction is led by Capital Cell and Andrea Giani, with the participation of current investor partners, including members of the Investors Club through Simon Fiduciaria, Italian Angels for Biotech and Bios Line Holding.
The funds will enable MgShell to accelerate the development and pre-clinical validation of its innovative technology, support product development, advance business development activities and strengthen the team. MgShell will continue to work to complete the development of the technology, with the aim of bringing it to market as quickly as possible and offering an innovative solution to doctors and patients.
“This investment represents a crucial step for MgShell, confirming the strength of our vision and the value of our technology. With the support of experienced and strategic investors, we are ready to accelerate our path towards clinical validation and market access. Our aim is to offer innovative and effective solutions for the treatment of eye diseases, significantly improving the quality of life of patients,’ says Marco Ferroni, CEO of MgShell, in a note.
Daniel Oliver, Director of Capital Cell, comments: ‘We are excited to support MgShell on its growth path. Their technology represents an innovative solution in an industry with a huge need for effective new therapies. We firmly believe in their potential and the team’s ability to turn this vision into reality.”
Andrea Giani, investor and retinal specialist, adds: ‘I am convinced that MgShell can revolutionise retinal therapies, addressing a still unmet clinical need thanks to its innovative technology. Its approach could reach current standards of efficacy and safety, reducing the therapeutic burden for patients, caregivers and physicians. It is a pleasure to support MgShell with its deep expertise and impressive research and development programme led by Marco Ferroni and Francesco De Gaetano.”
Enrico Gianotti, member of the Board and champion of the Investors Club, says: “This second round of investment represents a strong vote of confidence in MgShell and will play a crucial role in enabling the company to achieve its strategic goal of preclinical validation on schedule. While we recognise the importance and complexity of the steps still to be taken, we strongly believe that the strength, commitment and expertise of the team will be instrumental in bringing the project to a successful outcome.”
Federica Girolami, investor and champion of Italian Angels for Biotech, says: “I believe MgShell has the potential to revolutionise the ophthalmic sector. By developing a medical device that directly addresses critical unmet retinal health needs, this initiative has the potential to significantly improve clinical outcomes and quality of life for patients”.
“The Italian biotech sector needs companies like MgShell, capable of innovating and carrying out projects with a high scientific and clinical impact. We believe in the value of this technology and in the skills of the MgShell team to successfully reach the market responding to a clear and urgent need of patients,” says Lucio Rovati, investor and CEO of Rottapharm Biotech.
Paolo Tramonti, CEO of Bios Line Holding, adds: “After my experience with Next Sight, I recognised in MgShell the same potential for high-impact innovation in the ophthalmic field. Marco and his team demonstrated great executive capacity and a clear vision, which is why I decided to invest again.”
‘From an investment and governance perspective, MgShell stands out for its sound management and ability to achieve key objectives. We have full confidence in the direction taken and the long-term value of the project,’ concludes Stefano Gallucci, advisor to Bios Line Holding.
ALL RIGHTS RESERVED ©